Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$3.69
+0.3%
$4.00
$3.21
$8.06
$882.85M0.594.49 million shs3.11 million shs
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$8.64
+0.1%
$8.09
$5.20
$10.67
$1.17B1.151.35 million shs4.36 million shs
CryoPort, Inc. stock logo
CYRX
CryoPort
$7.41
+1.6%
$6.36
$4.58
$9.78
$371.52M1.85516,477 shs1.89 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$9.57
-4.8%
$11.83
$6.36
$47.45
$1.09B1.161.76 million shs4.65 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
0.00%+3.65%-8.44%-25.15%-39.61%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.00%+11.20%+8.14%+4.22%+56.81%
CryoPort, Inc. stock logo
CYRX
CryoPort
0.00%+16.33%+24.54%+21.67%+4.37%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-7.27%-21.81%-16.42%-71.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.4453 of 5 stars
3.53.00.04.42.72.50.6
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
2.7534 of 5 stars
3.51.00.00.02.80.81.9
CryoPort, Inc. stock logo
CYRX
CryoPort
3.2834 of 5 stars
4.42.00.00.01.92.50.6
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.4516 of 5 stars
4.53.00.00.02.52.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
3.00
Buy$10.89195.09% Upside
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
3.00
Buy$11.5033.10% Upside
CryoPort, Inc. stock logo
CYRX
CryoPort
2.71
Moderate Buy$11.0048.45% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.00
Buy$41.13329.73% Upside

Current Analyst Ratings Breakdown

Latest CYRX, ARDX, DYN, and AUPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/25/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/24/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$13.00
6/18/2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.00
6/17/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/11/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$37.00
6/2/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00 ➝ $34.00
5/29/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$46.00
5/9/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $38.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$333.61M2.65N/AN/A$0.73 per share5.05
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$235.13M4.96$0.31 per share28.01$2.68 per share3.22
CryoPort, Inc. stock logo
CYRX
CryoPort
$228.38M1.63N/AN/A$7.44 per share1.00
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$39.14M-$0.22N/A11.90N/A-14.86%-34.45%-13.81%7/30/2025 (Estimated)
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$5.75M$0.2830.8615.43N/A16.11%14.27%9.93%7/30/2025 (Estimated)
CryoPort, Inc. stock logo
CYRX
CryoPort
-$114.76M-$2.34N/AN/AN/A-50.15%-11.03%-5.54%8/5/2025 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)

Latest CYRX, ARDX, DYN, and AUPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
$0.08$0.16+$0.08$0.16$61.06 million$62.47 million
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/7/2025Q1 2025
CryoPort, Inc. stock logo
CYRX
CryoPort
-$0.23-$0.22+$0.01-$0.28$56.19 million$41.04 million
5/1/2025Q1 2025
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.10-$0.17-$0.07-$0.17$79.40 million$74.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
N/AN/AN/AN/AN/A
CryoPort, Inc. stock logo
CYRX
CryoPort
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.04
4.12
3.81
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
0.16
5.93
5.26
CryoPort, Inc. stock logo
CYRX
CryoPort
0.51
5.56
5.24
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
20.35
20.35

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
36.83%
CryoPort, Inc. stock logo
CYRX
CryoPort
92.90%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
4.80%
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
12.20%
CryoPort, Inc. stock logo
CYRX
CryoPort
10.00%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
14.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90239.26 million227.77 millionOptionable
Aurinia Pharmaceuticals Inc stock logo
AUPH
Aurinia Pharmaceuticals
300135.10 million118.62 millionOptionable
CryoPort, Inc. stock logo
CYRX
CryoPort
1,18650.14 million45.12 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million97.59 millionOptionable

Recent News About These Companies

Dyne Therapeutics (NASDAQ:DYN) Upgraded at Jones Trading
Dyne Therapeutics (NASDAQ:DYN) Now Covered by Jones Trading
Dyne Therapeutics' (DYN) Buy Rating Reiterated at Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$3.69 +0.01 (+0.27%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.70 +0.02 (+0.41%)
As of 06/27/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals stock logo

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.64 +0.01 (+0.12%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$8.62 -0.02 (-0.23%)
As of 06/27/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

CryoPort stock logo

CryoPort NASDAQ:CYRX

$7.41 +0.12 (+1.65%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$7.42 +0.00 (+0.07%)
As of 06/27/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$9.57 -0.48 (-4.78%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.48 -0.09 (-0.94%)
As of 06/27/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.